![[Images/pbms-and-wholesaler-msos-capture-biosimilar-value.png]]

## The Take

**$568B specialty drug market by 2026, with 9 of 10 top-selling drugs being specialty medications.** Vertical integrators have already captured the economics: PBM private-label biosimilars control 97% of formulary-preferred adalimumab; wholesaler-MSOs own $16B+ in physician practices; prior auth AI switching costs lock in early winners.

**The mechanism:** Specialty drugs represent 50%+ of drug spending but only 2% of prescriptions. This concentration creates winner-take-all dynamics where decision point ownership beats software. PBMs control formulary access (80% market share by Big 3). Wholesalers control buy-and-bill (90% market share by Big 3). AI platforms that capture specialty pharmacy PA first create "act of God" switching costs.

**Why now:** Three forces accelerating in 2025-2026:
1. **Biosimilar private labels matured.** Humira biosimilars went from 2% to 23% market share in 12 months once PBMs pushed conversions. Independent manufacturers without PBM deals have just 3% total share.
2. **340B faces structural pressure.** Program hit $81.4B in 2024 (+23%), but CMS is taking regulatory control from HRSA. IRA price negotiations compress the spread. Manufacturer restrictions cost $3.2B/year already.
3. **PA AI winners emerging.** Latent has 25+ health systems (Yale, Ochsner, Northwestern). Switching costs are extreme: "would need an act of God to switch." Epic building competing LLM but "behind."

**In 3-5 years:**
- **Winners:** CVS/Cigna/UNH (own PBM + specialty pharmacy + private labels); McKesson/Cardinal/Cencora (own GPO + distribution + practices); Latent Health (specialty pharmacy PA leader)
- **Losers:** Independent biosimilar manufacturers (3% share, 10% margins); pure 340B software (shrinking pool); infusion-only PA plays (wrong market segment); late PA entrants (lock-in too strong)
- **Market structure:** Top 3 PBMs + Top 3 wholesalers capture 85%+ of specialty drug value chain economics

**How this evolved:**
- *2026-01-07:* **MERGED** — Combined three separate theses (biosimilars, 340B, prior auth) under unified vertical integration frame
- *2026-01-08:* **REBUILD** — Added CPO interviews revealing analytics-first entry point ($400-500K willingness to pay)
- *2026-01-26:* **REBUILD** — Contrarian pressure test. Biggest threat: Harvard/RAND studies show vertical integration raises costs without improving quality. But thesis is about value capture, not patient outcomes—integrators win economically even if model is suboptimal. 340B grew to $81B but faces first year of structural pressure in 2026. FTC lawsuit against PBMs ongoing but no blocking action taken.

---

## Mechanism

**[Vertical integrators] capture [specialty drug economics] because [they own decision points (formulary control, practice ownership, PA automation)] → [standalone software and cash-poor providers lose]**

### 1. Biosimilars: Private Labels + Practice Ownership

**PBMs captured pharmacy-side biosimilars via private labels:**
- Nearly all marketed Humira biosimilars excluded from 2025-2026 formularies
- Each PBM favors own private label: Cordavis (CVS), Quallent (Cigna), Nuvaila (UNH)
- Independent manufacturers without PBM deals: **3% total market share**
- Manufacturer margins compressed to ~10% of list price after revenue sharing

**Wholesaler-MSOs captured buy-and-bill:**
- Big 3 spent **$16B+** on MSO acquisitions (oncology, GI, ophthalmology, urology)
- McKesson: Core Ventures ($2.5B for 70% stake in Florida Cancer Specialists)
- Cencora: OneOncology ($3.6B), Retina Consultants of America ($4.6B)
- Cardinal: GI Alliance ($3.9B majority stake), Specialty Networks ($1.2B)
- They capture 3-5x margins by steering biosimilars through owned practices

### 2. 340B: Five-Vector Squeeze (First Year of Structural Pressure)

The $81.4B gross program isn't disappearing, but 2026 marks the turning point.

**Threat 1: Manufacturer Restrictions ($3.2B/year losses)**
- 39+ manufacturers restrict 340B pricing for contract pharmacies
- Third Circuit upheld manufacturer rights—statute silent on distribution conditions
- 18 states passed protective legislation, but federal framework favors manufacturers

**Threat 2: CMS Regulatory Takeover**
- FY2026 budget proposes moving 340B from HRSA to CMS
- CMS surveying hospital acquisition costs—precursor to payment cuts
- Part D claims repository being built (voluntary now, mandatory soon)

**Threat 3: IRA List Price Compression**
- 10 drugs effective January 2026, 15 more 2027-2028, 20 more 2029+
- Maximum Fair Prices compress the 340B spread
- "A pharmacy earning $30 on a drug with $600 WAC would earn only $10 if WAC dropped to $200"

**Threat 4: Rebate Model Pilot (Paused but Looming)**
- 8 of 10 IRA-negotiated drug manufacturers approved for rebate pilot
- Entities purchase at WAC, wait 10 days for rebate
- Federal grantees "cannot float the funds"—creates capital stratification
- AHA lawsuit paused pilot December 2025, but manufacturers still pursuing

**Threat 5: Capital Stratification**
- Non-profit hospitals can float cash; FQHCs cannot
- 48% of rural hospitals operated at a loss in 2023
- Program benefits increasingly accrue to well-capitalized entities

### 3. Prior Auth AI: Specialty Pharmacy Captured, Infusion Lags

**Competitive Landscape (January 2026):**

| Company | Model | Focus | Traction | Funding | Assessment |
|---------|-------|-------|----------|---------|------------|
| **Latent** | Health system PA | Specialty pharmacy (Part D) | 25+ health systems | $50M Series B | **LEADER** |
| **Mandolin** | Infusion PA | Part B infusion | 700+ clinics; NO health systems | $57M total | Wrong market |
| **Tandem** | Pharma-funded | Provider-side branded drugs | 1,035 providers | $7M seed | Different game |
| **Foundation** | End-to-end | Specialty pharmacy ops | Early | $20M Series A | Watch |

**Why Latent wins:**
- Specialty pharmacy = 2-3x infusion revenue
- "When our IT teams like, 'We can only get one of these done in the next year, which one do you want?' It was we're obviously going to go at Latent because that's where the revenues are"
- Switching costs extreme: "Would need an act of God to switch"
- Planning to phase out CoverMyMeds for Latent

**Epic threat:**
- Building own LLM for prior auth automation
- New APIs scheduled February 2026
- "Penny" revenue cycle AI launching November 2026
- But Northwestern says Epic is "behind" Latent

---

## Bull Case

- [x] **PBMs control 97% of formulary-preferred biosimilars.** Independent manufacturers without deals have 3% total share ([[2025-12-23-the-big-three-pbms-2025-formulary-exclusions-humir]])
- [x] **Wholesaler-MSOs spent $16B+ on practice acquisitions.** McKesson, Cencora, Cardinal aggressively integrating oncology, GI, retina ([[The Future of Buy-and-Bill Market Access Five Drivers of Wholesalers' Vertical Integration with Physician Practices]])
- [x] **340B hit $81.4B in 2024 (+23%).** But Drug Channels says "2026 will be first year of structural pressure" from CMS/IRA
- [x] **Latent has extreme switching costs.** "Would need an act of God to switch" once implemented ([[mandolin---cone-health-e0b981fa]])
- [x] **CPO willingness to pay for analytics: $400-500K.** "If you equip a chief pharmacy officer to walk into the C-suite and say 'we have a $50M opportunity and we're only capturing $20M,' they're going to love you" ([[mandolin---cone-health-e0b981fa]])
- [x] **Specialty pharmacy is 2-3x infusion revenue.** CPO explicitly deprioritized Mandolin for Latent ([[mandolin---cone-health-e0b981fa]])

---

## Bear Case

- [ ] **FTC lawsuit against PBMs ongoing.** Filed Sept 2024, case resumed Aug 2025, PBMs filed motion to dismiss Sept 2025
- [ ] **Vertical integration may not deliver promised synergies.** Harvard study: integration leads to 50% higher prices, worse outcomes; Geisinger lost $842M in 2022
- [ ] **Epic building competing PA automation.** "Penny" AI suite launching Nov 2026 could commoditize PA automation
- [ ] **CVS breakup uncertainty.** If CVS spins off Caremark, could disrupt vertical integration model
- [ ] **State 340B protection laws spreading.** 18 states passed legislation requiring manufacturers to extend 340B pricing to contract pharmacies

## The Counter Thesis

**What would have to be true to be wrong:**

1. **FTC successfully blocks PBM vertical integration.** The lawsuit against big 3 PBMs for anticompetitive rebating would need to result in structural remedies—unbundling PBMs from pharmacies and specialty pharmacies. Current trajectory: motion to dismiss filed, no remedy in sight.

2. **Vertical integration fails economically.** The Harvard/RAND research shows integration raises prices without improving quality. If regulators or purchasers force integrators to demonstrate value rather than just capture it, the model unravels. Current trajectory: No enforcement mechanism exists.

3. **Epic commoditizes PA automation.** If Epic ships native PA automation that works well and is "free" to Epic shops, standalone vendors like Latent lose differentiation. Current trajectory: Epic "behind" but has massive distribution advantage.

4. **Independent biosimilar manufacturers break through.** Would require either (a) FTC action on formulary discrimination, (b) CMS mandating biosimilar parity, or (c) independent manufacturers building direct-to-patient channels. Current trajectory: Manufacturers without PBM deals have 3% share and 10% margins—not sustainable.

5. **340B program expands rather than contracts.** Would require Congress to strengthen HRSA authority, block CMS takeover, and override manufacturer restrictions. Current trajectory: $81B program but facing five-vector squeeze.

---

## Timeline

**Now → 2026:**
- 340B rebate pilot on hold (AHA lawsuit), but CMS building Part D claims repository
- PBM private-label biosimilars dominant in 2026 formularies
- Epic PA APIs launch February 2026
- Latent continues health system expansion

**2027 → 2028:**
- 30-40 biosimilar launches expected
- IRA price negotiation expands to Part B (2028)
- CMS 340B acquisition cost survey feeds into reimbursement cuts
- PA AI becomes standard for commercial payers
- **Inflection:** If independent biosimilar manufacturers exit or consolidate, thesis confirmed

**2029+:**
- PBM private labels default across pharmacy benefit
- Wholesaler-MSOs control majority of buy-and-bill volume
- 340B pool compressed but concentrated among fewer, larger players
- PA AI consolidated to 2-3 platforms per segment
- Epic potentially commoditizes PA, forcing Latent to differentiate on analytics

---

## Startup Opportunities

### What MAKES SENSE

**1. Specialty Pharmacy Analytics / Leakage Identification (HIGHEST CONVICTION)**
- Why this follows: CPO willing to pay $400-500K just for analytics. Creates business case for all other investments. No one does this well.
- Wedge: Real-time dashboard showing opportunity—what's leaking to external pharmacies, which physicians aren't capturing scripts, margin opportunity by drug/payer/clinic
- Risk: Epic could build natively; requires deep EHR integration

**2. 340B Capital Solutions / Float Financing**
- Why this follows: Rebate model (if resumed) creates 10-day cash gap. FQHCs can't float. Creates financing opportunity.
- Wedge: Provide capital to cash-constrained 340B entities to bridge rebate timing gap
- Risk: If rebate pilot permanently blocked, opportunity shrinks

**3. Provider-Side PA Automation (Tandem Model)**
- Why this follows: Different customer (providers), different payer (pharma), lower switching costs than health system deals
- Wedge: Pharma-funded PA automation distributed to prescribers via EHR
- Risk: Tandem has first-mover in pharma relationships

**4. Specialty Pharmacy Build/Operate Services**
- Why this follows: Software loses to ownership. Services enable ownership.
- Wedge: Help health systems build and operate owned specialty pharmacies—accreditation, compliance, launch, management
- Risk: Service-heavy, harder to scale

### What DOES NOT Make Sense

**1. Infusion-Only PA Automation (Competing with Mandolin)**
- Specialty pharmacy is 2-3x the money
- Mandolin has $57M raised and still hasn't cracked health systems
- CPO explicitly deprioritized infusion for specialty

**2. Pure PA Automation for Health Systems (Competing with Latent)**
- Latent has first-mover with lighthouse accounts
- $50M raised, General Catalyst backing
- Extreme switching costs once implemented

**3. Pure 340B Savings Maximization Software**
- The pool is under structural pressure
- Vertical integrators capturing remaining value through ownership
- Incumbents (Sentry, Kalderos) own compliance layer

**4. Biosimilar Adoption Software**
- 340B hospitals incentivized NOT to adopt biosimilars (larger spread on branded)
- PBM rebate walls are real gatekeeper
- Vertical integrators already captured the economics

---

## Watch For

**If RIGHT (thesis plays out):**
- Independent biosimilar manufacturers exit market or consolidate (look for Q2-Q3 2026)
- Wholesaler-MSO owned practices exceed 40% of specialty volume
- Health systems announce prior auth staff reductions with AI replacement
- FTC lawsuit dismissed or settles without structural remedies
- CMS 340B acquisition cost survey leads to payment cuts (2027)
- Epic PA automation delayed or underwhelms

**If WRONG (thesis fails):**
- FTC mandates PBM-pharmacy unbundling or formulary transparency
- Independent biosimilar manufacturer reaches 25%+ market share
- 340B program growth accelerates despite regulatory pressure
- Epic ships PA automation that health systems prefer over Latent
- Software-only company achieves $50M+ ARR without integrator partnership
- CVS breakup leads to independent Caremark willing to work with all biosimilar manufacturers

---

## Evidence

### Biosimilar/Vertical Integration Evidence
| Date | Source | Type | Key Signal |
|------|--------|------|------------|
| 2026-01-26 | Drug Channels 2026 | Research | "Independent manufacturers without PBM deals have 3% total share; formulary exclusions will no longer deliver economic power they once did" |
| 2025-12-23 | [[2025-12-23-the-big-three-pbms-2025-formulary-exclusions-humir]] | Research | "Nearly all Humira biosimilars excluded"—private labels dominate PBM formularies |
| 2025-10-21 | [[The Future of Buy-and-Bill Market Access Five Drivers of Wholesalers' Vertical Integration with Physician Practices]] | Research | Big 3 wholesalers spent $16B+ on MSO acquisitions |
| 2026-01 | JMCP/PMC | Research | "6 manufacturers without PBM private-label arrangement have 3% market share total; manufacturer profit may be only 10% of list price" |
| 2025-12-28 | [[specialty-pharma-autoimmune-ba34628610be40a1b149b83ea01983cc-cea8df03]] | Research | "Top 3 PBMs have 80% market share, top 3 wholesalers have 90%+" |

### 340B Evidence
| Date | Source | Type | Key Signal |
|------|--------|------|------------|
| 2025-12 | Drug Channels | Research | "340B hit $81.4B in 2024 (+23%); 2026 will be first year of structural pressure" |
| 2025-11 | [[The 340B Rebate Pilot Model Weighing 340B Program Integrity Against Financial Stability For The Safety Net  Health Affairs Forefront]] | Policy | "Federal grantees have far fewer resources to cope with waiting for 340B discount." Original program changed FROM rebate TO upfront discount. |
| 2025-12 | NACHC | Policy | 39+ manufacturers restrict 340B for contract pharmacies; $3.2B annual losses |
| 2025 | Jones Day | Legal | "Third Circuit rejected HRSA's expansive interpretation; statute silent about delivery to contract pharmacies" |
| 2025-12 | 340B Report | Policy | 18 states passed legislation requiring manufacturers to extend 340B pricing to contract pharmacies |

### Prior Auth AI Evidence
| Date | Source | Type | Key Signal |
|------|--------|------|------------|
| 2026-01-08 | [[mandolin---cone-health-e0b981fa]] | Operator | "Specialty is where all the money is." CPO chose Latent over Mandolin. "Would need an act of God to switch." |
| 2026-01-08 | [[latent---northwestern-55b5fe6b]] | Operator | "Specialty pharmacy generates second most revenue outside oncology." Planning to phase out CoverMyMeds for Latent. Epic "behind." |
| 2025-08 | Epic UGM | News | Epic developing ~200 AI features including PA automation; "Penny" RCM AI launching Nov 2026 |
| 2026-01-08 | [[mandolin---cone-health-e0b981fa]] | Operator | CPO willing to pay $400-500K just for specialty pharmacy analytics. "No one does this well." |
| 2025-12 | [[2025-12-30_Latent-Health]] | Research | Latent: $50M Series B, 25+ health systems, 97% clinical accuracy |
| 2026-01 | Menlo Ventures | Research | "AI prior authorization spending growing 10x year-over-year from $10M in 2024 to $100M in 2025" |

### Vertical Integration Criticism Evidence
| Date | Source | Type | Key Signal |
|------|--------|------|------------|
| 2025 | Harvard Kennedy School | Research | "Physicians significantly alter care process after integration; substantial increases in post-procedure complications" |
| 2025 | RAND | Research | "Consolidation is taking on new forms; effort has failed to find evidence consolidation lowers costs or improves quality" |
| 2023 | Healthcare Blog | Analysis | "Geisinger lost $842M in 2022; raises serious questions about viability of vertically integrated model" |
| 2025 | FTC | Regulatory | FTC filed lawsuit against 3 largest PBMs for anticompetitive rebating practices; case resumed Aug 2025 |

### Specialty Pharmacy Economics Evidence
| Date | Source | Type | Key Signal |
|------|--------|------|------------|
| 2026-01-08 | [[Sources/Granola/George Liang and Emre Karatas-2026-01-08_10-06-37]] | Granola | "$350K additional margin per oncologist from specialty drug optimization; Trastuzumab has 7 biosimilar options—hospital using least profitable" |
| 2025-04 | Drug Channels | Research | "Three largest specialty pharmacies generated two-thirds of all prescription revenues from pharmacy-dispensed specialty drugs" |
| 2026 | Mercer | Research | "Specialty pharmaceutical industry expected to hit $568 billion in 2026; 9 of 10 best-selling drugs by revenue will be specialty" |

---

## Open Questions

**Will FTC lawsuit result in structural remedies?**
→ OPEN: Motion to dismiss filed Sept 2025. If dismissed or settled without unbundling, thesis confirmed. If structural remedy imposed, market structure changes.

**Will Epic commoditize PA automation?**
→ OPEN: APIs launching Feb 2026, Penny launching Nov 2026. If Epic ships competitive native solution, Latent must differentiate on analytics/service. Northwestern says Epic "behind" but this could change.

**Will 340B rebate pilot resume?**
→ OPEN: Paused by AHA lawsuit Dec 2025. If resumed, creates capital stratification opportunity. If permanently blocked, one pressure vector removed.

---

## Related Theses

- [[GLP-1s Force PBM Transparency and Channel Disruption—Digital-First Captures 20%+ Share by 2028]]
- [[Payer Infrastructure Modernizes—Pre-Pay AI and Cloud CAPS Capture Mid-Market by 2028]]

---

*Confidence: HIGH — 40+ sources including 3 CPO/pharmacist operator interviews. Core mechanism (vertical integrators capture value through decision point ownership) validated across biosimilars, 340B, and PA. Key contrarian finding (integration raises costs without improving outcomes) doesn't break thesis—integrators win economically even if model is suboptimal for patients. Regulatory risk is real (FTC lawsuit) but no blocking action taken.*
*Last rebuilt: 2026-01-26*
*Contrarian threats: Harvard/RAND research shows vertical integration fails to improve quality or costs. But thesis is about value capture, not patient outcomes. FTC lawsuit ongoing but no structural remedy in sight. Epic building competing PA automation but "behind" Latent.*
